Immunic secures private funding for clinical stage studies

Mugglehead
By Joseph MortonOct 11, 2022, 7:22 pm218 pts
Immunic (NASDAQ:IMUX) entered into a securities purchase agreement with select investors to issue and sell 8,696,552 shares of its common stock at a price of USD$4.35 per share, reflecting a 10% premium to the closing price on October 7, 2022 on NASDAQ. The private investment in public equity (PIPE) financing…

Read Article Share
Share Article
- email
- twitter
- facebook
- pocket
- reddit
- tumblr
- linkedin
- pinterest

Trending Today on NewsBudz

Why Is Texas Supporting Psychedelics Research While Criminalizing Cannabis? (Op-Ed) 61

Blow Smoke, Not Your Cover with New Smokebuddy Bundles 51

About NewsBudz

NewsBudz is your go-to app for daily cannabis news, covering everything from medical marijuana breakthroughs to recreational cannabis trends and legalization updates.

Our platform aggregates content from over 30 top-tier cannabis news outlets to deliver a curated stream of the latest headlines, insights, and developments across the marijuana and hemp industries.

Whether you're interested in policy reform, health research, cannabis business, CBD, delta 9 products or lifestyle stories, NewsBudz keeps you informed and connected. Accessible on the web and mobile, NewsBudz makes it easy to explore, read, and share cannabis news anytime, anywhere.